General
Preferred name
AVANAFIL
Synonyms
TA1790 ()
4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-N-[(pyrimidin-2-yl)methyl]pyrimidine-5-carboxamide ()
TA-1790 ()
Spedra ()
Stendra ()
Avanafil-13C-d3 ()
P&D ID
PD000128
CAS
330784-47-9
2738376-89-9
Tags
available
drug
Approved by
EMA
FDA
First approval
2012
2011
Drug Status
approved
Drug indication
Erectile dysfunction
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ABSORPTION Avanafil is rapidly absorbed and does not accumulate following multiple doses. ; Tmax = 30 - 45 minutes;; Time to peak response = 10 minutes (20 minutes shorter than sildenafil)
DESCRIPTION Avanafil is a phosphodiesterase type 5 inhibitor. (GtoPdb)
Compound Sets
20
AdooQ Bioactive Compound Library
A12619
Cayman Chemical Bioactives
23024
31687
ChEMBL Approved Drugs
CHEMBL1963681
ChEMBL Drugs
CHEMBL1963681
Drug Repurposing Hub
DrugBank
DB06237
DrugBank Approved Drugs
DB06237
DrugCentral
4305
DrugCentral Approved Drugs
4305
DrugMAP
DM75CXN
DrugMAP Approved Drugs
DM75CXN
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101381
Guide to Pharmacology
7448
MedChem Express Bioactive Compound Library
HY-18252
NCATS Inxight Approved Drugs
DR5S136IVO
ReFrame library
Selleckchem Bioactive Compound Library
avanafil
TargetMol Bioactive Compound Library
T2334
The Spectrum Collection
External IDs
35
Properties
(calculated by RDKit )
Molecular Weight
483.18
Hydrogen Bond Acceptors
9
Hydrogen Bond Donors
3
Rotatable Bonds
9
Ring Count
4
Aromatic Ring Count
3
cLogP
2.43
TPSA
125.39
Fraction CSP3
0.35
Chiral centers
1.0
Largest ring
6.0
QED
0.42
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Metabolism
Immunology/Inflammation
Metabolic Enzyme/Protease
Target
PDE5
PDE5A
Endogenous Metabolite
NO Synthase
Phosphodiesterase (PDE)
PDE
Indication
erectile dysfunction
MOA
phosphodiesterase inhibitor
Source data